The Feasibility of Edoxaban for Asymptomatic Cancer-associated Thrombosis in Japanese Gastrointestinal Cancer Patients (ExCAVE study)

Michio Nakamura (✉ michio.nakamura@icloud.com)

Sapporo City General Hospital

Atsushi Ishiguro

Teine Keijinkai Hospital

Masayoshi Dazai

Sapporo Medical Center NTT EC

Yasuyuki Kawamoto

Hokkaido University Hospital

Satoshi Yuki

Hokkaido University Hospital

Susumu Sogabe

KKR Sapporo Medical Center

Ayumu Hosokawa

University of Miyazaki Hospital

Kentaro Sawada

Kushiro Rosai Hospital

Osamu Muto

Japanese Red Cross Akita Hospital

Naoki Izawa

St. Marianna University School of Medicine

Koji Nakashima

University of Miyazaki Hospital

Yoshiki Horie

St. Marianna University School of Medicine

Masataka Yagisawa

Japanese Red Cross Kitami Hospital

Shinya Kajiura

Toyama University Hospital

Takayuki Ando

University of Toyama

Yosuke Mitsuhashi

IMS Sapporo Digestive Disease Center General Hospital

Yu Sunakawa

St. Marianna University School of Medicine

Yasuka Kikuchi

Hokkaido University

Yoshito Komatsu

Hokkaido University Hospital

Research Article

Keywords: thrombosis, edoxaban, gastrointestinal cancer, bleeding, heparin

Posted Date: December 16th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-1059233/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Although an initial therapy with a parenteral anticoagulant is required before edoxaban, this strategy is frequently avoided in actual clinical practice because of its complexity. This study assessed the feasibility of edoxaban without initial heparin usage for asymptomatic cancer-associated thrombosis (CAT) in Japanese patients with gastrointestinal cancer (GIC) at a high risk of bleeding.

Methods

In this multicenter prospective feasibility study conducted at 10 Japanese institutions, patients with active GIC who developed accidental asymptomatic CAT during chemotherapy were recruited. Edoxaban was orally administered once daily without initial parenteral anticoagulant therapy within 3 days after detecting asymptomatic CAT. The primary outcome was the incidence of major bleeding (MB) or clinically relevant non-major bleeding (CRNMB) during the first 3 months of edoxaban administration.

Results

Of the 54 patients enrolled from October 2017 to September 2020, one was excluded because of a misdiagnosis of CAT. In the remaining 53 patients, the primary outcome occurred in six patients (11.3%). MB occurred in four patients (7.5%), including gastrointestinal bleeding in three patients and intracranial hemorrhage in one patient. CRNMB occurred in two patients (3.8%), including bleeding from the stoma site and genital bleeding in one patient each. There were no deaths attributable to bleeding, and all patients who had experienced MB and CRNMB recovered.

Conclusions

The risk of bleeding after edoxaban without heparin pretreatment was acceptable, demonstrating new treatment options for asymptomatic CAT in patients with GIC.

Introduction

Cancer-associated thromboembolism (CAT) is a critical life-threatening complication among patients with cancer, occurring in approximately 7%–15% of patients with cancer.[1-4] Although several guidelines recommended low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs) for CAT[5-8], LMWH is not approved by Japanese public medical insurance for use as an anticoagulant against CAT. Therefore, DOACs are currently the most recommended treatments for CAT in Japan. Whereas DOACs have the advantages of oral administration and easy dosing, which might enhance patient compliance, they have been reported to carry a risk of gastrointestinal (GI) bleeding.[9-11] In particular, DOACs are not recommended as first-line treatments for patients with luminal GI cancer (GIC) with a primary tumor or active GI mucosal abnormalities (e.g., gastric/duodenal ulcer, gastritis, colitis, esophagitis).[7, 12] Most recently, the National Comprehensive Cancer Network guidelines indicated that apixaban, edoxaban, or

rivaroxaban are preferred for patients other than those with gastric or gastroesophageal lesions with higher bleeding rates.[13]

When using DOACs in patients with GI malignancy, evaluating the risk–benefit balance in individual cases is essential. Of the three DOACs with direct factor Xa inhibitory effects, both apixaban and rivaroxaban are approved for the initial treatment period. However, edoxaban requires an initial treatment with a parenteral anticoagulant such as unfractionated heparin (UFH), and there are no data regarding the safety and efficacy of edoxaban treatment without heparin pretreatment. In the ETNA-VTE Japan study, which provided real-world data about edoxaban use in Japan, it was reported that only 56.1% of patients received prior anticoagulant therapy before using edoxaban, and edoxaban alone was used in approximately half of the patients.[14] Edoxaban has a shorter time to active onset than apixaban and rivaroxaban,[7] and heparin administration before edoxaban treatment may be omitted in patients with asymptomatic thrombosis who do not require urgent treatment. The use of UFH as an initial treatment requires inpatient management with continuous intravascular infusion, repeat venipuncture for monitoring (anti-factor Xa levels or activated partial thromboplastin time), and dose adjustment. In addition, inpatient treatment for patients with asymptomatic CAT is inconvenient and costly; thus, a clinical need to omit prior heparin administration before using edoxaban exists for patients with asymptomatic CAT.

In the ExCAVE study, a multicenter prospective feasibility study of edoxaban for asymptomatic CAT in Japanese patients with GIC and a high bleeding risk, we assessed whether an initial UFH treatment could be omitted in this setting.

Patients And Methods

Study design

ExCAVE is a single-arm, multicenter prospective feasibility study. The enrollment period was from October 2017 to September 2020. The protocol was performed in accordance with the Declaration of Helsinki, Japanese ethical guidelines on clinical research, and Ethical Guidelines for Clinical Studies. The study was registered with the Japan Registry of Clinical Trials (jRCTs011180030) and the University Hospital Medical Information Network Clinical Trials Registry (protocol ID UMIN000028517) on 23/06/2017. Written informed consent was obtained from all patients. The institutional review board at each participating center approved the protocol.

Patients

Patients with histologically confirmed GI malignancy who were undergoing systemic chemotherapy and who were newly diagnosed with incidental, asymptomatic deep-vein thrombosis (DVT) in the lower (popliteal, femoral, or iliac vein) or upper limbs (subclavian or internal jugular vein) or asymptomatic pulmonary embolism (PE) during chemotherapy were eligible to participate in this study. Incidental DVT or PE was detected on imaging performed for reasons other than clinical suspicion of venous

thromboembolism (VTE). Patients with symptomatic CAT were excluded from the study. In the case of DVT, signs such as erythema, warmth, pain, swelling, tenderness, and pain during dorsiflexion of the legs were defined as “symptomatic,” and in the case of PE, signs such as sudden dyspnea, frequent breathing, tachypnea, fainting, hypotension, and hypoxia were defined as “symptomatic.” New diagnosed DVT was defined as newly occurring thrombosis in cases with a confirmed serum D-dimer level of 1.2 µg/mL or less in the period before study enrollment. Even in patients with serum D-dimer levels above 1.2 ug/mL, cases in which it was confirmed by chest and abdominal contrast computed tomography (CT) or venous ultrasonography that there was no thrombosis before enrollment were also treated as new-onset DVT, and registration for the study was permitted. The other inclusion criteria and exclusion criteria—including patients’ clinical characteristics, issues related to anticoagulant treatment, bleeding risk, and problems standard from clinical trials of anticoagulant agents—are listed in the Supplementary Appendix.

Trial treatment

Edoxaban was administered without prior heparin administration in this study, orally at a fixed dose once daily and at a lower dose (30 mg once daily) in patients with creatinine clearance (CrCl) of ≤ 50 mL/min or body weight of ≤ 60 kg, as well as in patients receiving concomitant treatment with potent P-glycoprotein inhibitors. In all patients, treatment with edoxaban continued for at least 3 months, and the treating physician determined the duration beyond 3 months.

Outcome assessment

The primary outcome was a composite of major bleeding (MB) and clinically relevant non-major bleeding (CRNMB) during the 3-month study period. MB was defined as clinically overt bleeding associated with a decrease in the hemoglobin level of at least 2 g/dL, the transfusion of at least two units of red cells, bleeding occurring at a critical site (e.g., intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, or intramuscular with compartment syndrome), or fatal bleeding as per the criteria of the International Society on Thrombosis and Haemostasis.[15] CRNMB was defined as clinically overt bleeding not meeting the criteria for MB but requiring medical attention, causing discomfort, or impairing activities of daily living.[16] The criteria for evaluating VTE and the secondary endpoints are provided in the Supplementary Appendix. Regarding the imaging test used for the evaluation of thrombosis, the test immediately before the start date of Edoxaban administration was used as the baseline, and those within 28 days before administration were allowed. In addition, the evaluation after three months was allowed up to 2 weeks before and after the three-month elapsed date. The results of contrast-enhanced CT examinations performed to determine the effectiveness of treatment during the three-month study period were also allowed to evaluate thrombosis. Regarding the validity of the CAT diagnosis and determination of thrombus recurrence, a single independent radiological specialist, without additional clinical information, reviewed the imaging data that triggered the diagnosis of CAT and the subsequent imaging data.

Safety and tolerability

Study physicians assessed safety and tolerability at each visit for chemotherapy. Whether adverse effects were related to the study drug was evaluated by a study physician when reporting each event.

Statistical analysis

For categorical variables, the proportion was calculated, and contingency tables were created. The chi-squared test was used to compare categorical variables, and Fisher's exact test was used when the frequency of any cell of the contingency table was ≤ 5 . For continuous variables, summary statistics (mean, standard deviation) were calculated. For each risk factor for bleeding and VTE recurrence, the incidence (95% confidence interval [CI]) was estimated. In this study, if the one-side range width of the 95% CI of the primary outcome was within 9%, it was judged that the accuracy was sufficient for estimating the primary outcome. Assuming that the incidence of MB or CRNMB was 12% at the same level as in the Hokusai VTE Cancer subset analysis, the required sample size was estimated to be 80 to maintain a one-side width of the 95% CI of 8.9%. We estimated that 100 cases would be needed to achieve the required number of subjects during the patient accrual (2 years) and follow-up periods (3 months) assuming 20% attrition. Time-to-event curves were calculated using the Kaplan–Meier method. Statistical significance was set at $P < 0.05$. Statistical calculations were performed using SPSS for Macintosh (release 24.0; SPSS Inc., Chicago, IL, USA) and R for macOS (version 4.1.0, The R Foundation for Statistical Computing Platform).

Results

Patient characteristics

From October 2017 to September 2020, 54 patients were enrolled at 10 Japanese institutions (Figure 1). One patient was excluded because of a misdiagnosis of CAT. The full analysis set (FAS) for assessing the primary outcome included 53 patients (28 men, 25 women; age, 38–83 years; median age, 65.3 years). Table 1 presents the baseline characteristics of the FAS. Regarding the daily dose at the start of edoxaban treatment, 1.9, 58.5, and 39.6% of patients received doses of 15, 30, and 60 mg, respectively. Details about the dosage levels and dose adjustment factors (DAFs) are presented in Figure 2. All patients with DAFs ($n = 29$, 54.7%) received edoxaban 30 mg. Of the patients without DAFs ($n = 24$, 45.3%), 87.5% ($n = 21$) received edoxaban 60 mg. Thus, 50 patients (94.3%) received edoxaban at the recommended dosage. Of the three patients (5.7%) who received a non-recommended dosage: all three received a reduced dose (30 mg for two patients [3.8%] and 15 mg for one patient [1.9%]).

Primary outcome

The primary endpoint occurred in six patients (11.3%). Specifically, MB occurred in four patients (7.5%), including three cases of gastrointestinal bleeding and one case of intracranial hemorrhage. CRNMB occurred in two patients (3.8%), including one patient each with bleeding from the stoma and genital bleeding. There were no deaths attributable to bleeding, and all patients recovered. The time to occurrence of the primary outcome is presented in Figure 3, and the characteristics of these events are

presented in Table 2. The actual number of registered cases in this study was 53, which did not reach the expected number of 100. However, the one-side range of the 95% CI based on the binomial distribution of the primary event occurrence rate of 11.3% in this study was 9.38%, which was similar to the initially assumed rate, and it was appropriate for accurately evaluating the primary outcome.

Secondary outcomes

The combined endpoint of thrombus recurrence and death occurred in five patients (9.4%; Figure 3C). Recurrent CAT occurred in three patients (5.7%), including one patient with newly symptomatic PE and two patients with apparent increases in the thrombus volume versus baseline. Meanwhile, three patients died (5.7%), including two deaths attributable to cancer progression and one sudden death of unknown cause. The thrombus volume decreased in nine patients (17.0%), and the thrombus disappeared in 35 patients (66.0%), giving a thrombus reduction rate of 83.0%. The average time to disappearance in cases of thrombosis disappearance was 62.1 ± 18.2 days (range, 25–98; Table 3). Regarding the evaluation of thrombosis, validation was performed in a central review using imaging data with clinical information hidden, but multiple thromboses were found in seven patients. Therefore, the results of the central review were not reflected in the combined endpoint of thrombus recurrence and death.

Continuation or discontinuation of treatment and treatment duration

Of the 53 patients included in the FAS, 10 (18.9%) discontinued treatment during the study period. The reasons for discontinuation were bleeding-related AEs in four patients, thrombus disappearance in four patients, and primary cancer exacerbation in two patients. The mean duration of edoxaban treatment during the observation period was 81.1 ± 18.7 days, including durations of 84.6 ± 13.3 and 53.5 ± 31.2 days in patients without ($n = 47$) and with bleeding events ($n = 6$), respectively.

Subgroup analyses

There was no statistically significant difference in outcomes according to the presence of DAF (Figure 4), edoxaban administration dose (15 mg vs. 30 mg vs. 60 mg; Figure 5), primary cancer site (Figure 6), renal function (CrCl : ≤ 50 mL/min vs. >50 – 80 mL/min vs. >80 mL/min; Figure 7), body weight (≤ 60 kg vs. >60 kg; Figure 8), and age (<75 years vs. ≥ 75 years old; Figure 9).

Adverse events

The adverse events reported in this study are presented in Table 4. The most common bleeding event was epistaxis, occurring in seven patients (13.2%), although no events were serious.

Discussion

In this challenging ExCAVE study, which evaluated the safety and efficacy at three months to investigate the short-term effects of edoxaban when prior heparin administration is omitted in patients with GIC at high risk of bleeding, the incidence of MB or CRNMB, thrombus exacerbation or recurrence by either the

central or the physician's judgment, and death from all causes were 11% (n=6), 9% (n=5), and 6% (n=3), respectively. On the other hand, in the analysis of events that occurred during first 6 months in Hokusai VTE Cancer, which was given prior heparin administration when edoxaban was used, the incidence of MB or CRNMB, VTE recurrence, and death was 16%, 7%, and 27%, respectively. [16]

Since Hokusai VTE Cancer evaluated the safety and efficacy at six months, it cannot be directly compared with this ExCAVE study; however, a report on supplement data of Hokusai VTE Cancer showed that the event-free survival rate at three months was 78% (407/522). In the ExCAVE study, the event-free survival rate in the absence of events, including bleeding, thrombus recurrence, and death, was 85% (45/53), suggesting that omitting heparin leads may yield results comparable to those previously reported. The observation period in this study was 3 months, and the long-term safety of this strategy was not verified. However, at least no severe adverse events were observed during the observation period.

Edoxaban is the only fixed dose orally disintegrating DOAC tablet that can be taken once daily without scheduled titration. In addition, dose reduction criteria have been established for this drug to reduce the risk of bleeding, and the dose can be easily adjusted according to patients' body weight and renal function. However, the edoxaban single-drug approach without prior heparin administration is currently deprecated [5-8, 13] and requires cumbersome procedures when using edoxaban. In Hokusai-VTE study, a 5-day course of initial treatment of heparin (enoxaparin or UFH), a global standard that was proven to be useful at the time, was incorporated into the study design. Since then, prior administration of heparin is recommended for the use of edoxaban, and the package insert also states that edoxaban should be administered after appropriate initial treatment with a parenteral anticoagulant such as UFH. It is beneficial for patients to have edoxaban as an additional dose-adjustable DOAC option available without prior heparin administration for asymptomatic thrombosis.

Although several reports have discussed the efficacy and safety of DOACs for CAT,[16-18] few studies focused on incidental asymptomatic CAT. For example, in the Sapporo CAT study, our previously reported observational study of CAT, only 43% of patients were treated for asymptomatic thrombosis.[2] Conversely, Gary et al. reported that asymptomatic venous thrombotic events were associated with poor survival.[19] However, inpatient treatment for asymptomatic thrombosis is excessive because heparin administration requires hospitalization, which imposes a heavy burden on patients in terms of cost. It has also been reported that rivaroxaban and edoxaban are less expensive than LMWH for the treatment of CAT, and DOACs are effective options as anticoagulant therapies for asymptomatic CAT even from the viewpoint of cost.[20]

Generally, compared to the risk profile of dalteparin, edoxaban[10] and rivaroxaban[18] carry higher risks of MB in patients with GIC, and these DOACs should be used with caution in patients with unresected intraluminal tumors. By contrast, apixaban has been reported to have a bleeding rate equivalent to that of dalteparin in the treatment of CAT in patients with GIC.[21] Moreover, a report indicated that apixaban has the most favorable safety profile (MB risk) in a head-to-head comparison of three DOACs (dabigatran, apixaban, and rivaroxaban).[22] However, no clinical trials have directly compared the safety profiles of

DOACs in the treatment of CAT, and the safest DOAC for patients with CAT and GIC is unclear. Even when using apixaban, care should be taken when in patients with CAT and active GIC. That is, appropriate dose adjustment for at-risk patients is of paramount importance in bleeding risk management when using DOACs. In fact, more than half of the patients in this trial had at least one DAF, and all such patients underwent adequate dose adjustment to 30 mg.

Although no statistically significant difference was observed in this study, the frequency of bleeding events was slightly higher in the dose-adjusted group, suggesting that the frequency of bleeding might have increased further without dose reduction in patients with risk factors for bleeding, such as low body weight or low CrCl. In addition, in the present study, it is also important to note that PE occurred in one patient who did not undergo dose adjustment. In this patient, a dose of 60 mg should have been administered, but the dose was reduced to 30 mg at the attending physician's discretion. Thus, this indicated that the inappropriate dose reduction could be detrimental to the patients. The incidence of under-dosing of DOACs was investigated in the RIETE registry, which enrolled patients with VTE receiving DOACs.[23] In that study, 17% of patients receiving rivaroxaban and 50% of those receiving apixaban received a lower than recommended dose, far exceeding the rate in the present study (5.7%). Low inappropriate doses during initial therapy represent an essential advantage for edoxaban, for which the dose-setting criteria are clear.

The results of large-scale randomized controlled trials of apixaban[24] and rivaroxaban[25] as primary prophylactic treatments for CAT have been reported in recent years, but clinical studies on the prophylactic efficacy of edoxaban for CAT have not yet been conducted. The reason may be that prior heparin administration is recommended before edoxaban administration, and if heparin pretreatment were not required, edoxaban can also be considered an option for prophylactic treatment. It has been reported that 75% of MB events associated with DOACs occur in patients with unresected GI tumors.[26] In other words, edoxaban can be used in cases in which the primary lesion was surgically removed. In addition, edoxaban, which is an orally disintegrating formulation, can be an easy-to-use drug for CAT prevention, especially during the postoperative period, even in cases of GIC in which the feeding condition is poor because of loss of appetite after surgery.

There are several mechanisms by which DOAC causes bleeding, such as incomplete absorption, direct mucosal damage, and inhibited mucosal repair.[27] Because DOACs are administered in their active forms, the local action on the GI tract associated with drug retention may cause GI mucosal damage.[28] In addition, the difference of the higher peak serum drug concentration between once daily and twice-daily dosing for DOACs and the difference of the bioavailability of each drug may also contribute to the different bleeding risks of DOACs. There was no significant difference in the risk bleeding events in this study associated with the use of gastroprotective agents (including proton-pump inhibitors [PPIs] and histamine type-2 receptor antagonists) in this study (data not shown). However, one report stated that PPIs suppress the GI bleeding risk associated with DOAC.[29, 30] Before patients receive DOACs, it is crucial to assess the presence of primary residual lesions and GI mucosal damage and employ sufficient measures such as PPI administration for patients with a high risk of bleeding.

This study had notable limitations. First, it was a single-arm, prospective, interventional study without a control arm. To examine whether heparin administration can be omitted, it is necessary to set a group that received prior heparin administration as a control arm. However, setting up such a control arm wasn't easy because participants were less likely to accept the heparin-treated group that required hospitalization for treating asymptomatic CAT. Second, the sample size was small, as the number of enrolled patients was approximately half of the target. One reason for the slow patient accrual was that this was a challenging clinical study targeting GIC, which carries a high risk of bleeding, and the COVID-19 pandemic may have also affected patient recruitment. However, as mentioned previously, the obtained results were similar to the accuracy assumed for evaluating the primary outcome, and it is considered that the results have specific implications. Third, the observation period was short (3 months), and the long-term effects have not been evaluated. Since the purpose of this study was to evaluate feasibility only at the early stage of the introduction of edoxaban without heparin, we dared to evaluate it for three months instead of 6 months. The protocol allowed each attending physician to decide whether to continue treatment or change the drug after 3 months. A further consideration is needed regarding the long-term impact of this strategy.

Conclusions

To our knowledge, this is the first study to evaluate the feasibility of edoxaban without initial heparin usage. Although the edoxaban single-drug approach is an acceptable new option for asymptomatic CAT, further studies are needed on whether prior heparin dosing is essential when using edoxaban and in what cases it can be omitted.

Abbreviations

CAT: cancer-associated thrombosis; CI: confidence interval; CrCl: creatinine clearance; CRNMN: clinically relevant non-major bleeding; CT: computed tomography; DAFs: dose adjustment factors; DOACs: direct oral anticoagulants; DVT: deep-vein thrombosis; FAS: full analysis set; GI: gastrointestinal; GIC: gastrointestinal cancer; LMWH: low-molecular-weight heparin; MN: major bleeding; PE: pulmonary embolism; PPIs: proton-pump inhibitors; UFH: unfractionated heparin; VTE: venous thromboembolism

Declarations

Acknowledgment:

We thank all of the participants and their families, and the investigators for their patient recruitment and technical advice. MN and YK had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The authors also would like to express sincere thanks to Mari Sekiguchi and Kayoko Iuchi for their secretarial help and Enago (www.enago.jp) for the English language review.

Ethics approval and consent to participate: This study was carried out in accordance with the Declaration of Helsinki, and the protocol was approved by the Institutional Review Board of each participating center and Hokkaido University Certified Review Board (CRB1180001). This study was registered with the Japan Registry of Clinical Trials (trial identifier: jRCTs011180030) and UMIN Clinical Trials Registry (trial identifier: UMIN000028517). Written informed consent was obtained from all participants.

Author's contributions:

MN and YK participated in entire coordinating of the study, design and writing of the protocol, data collection, data analysis, data interpretation, and writing the manuscript. All authors participated in provision of study materials or patients, collection and assembly of data, data analysis, data interpretation, manuscript writing, and final approval of manuscript.

Funding:

This work is conducted as a research of Hokkaido Gastrointestinal Cancer Study Group with funding from Daiichi Sankyo Co., Ltd. (Tokyo, Japan). The funder approved the study proposal but had no role in the collection, analysis, or interpretation of data or writing of the report.

Availability of data and materials:

All data generated or analyzed during the current study are available from the corresponding author on reasonable request.

Consent for publication: Not applicable

Competing interests: MN and YS have received honoraria from Daiichi Sankyo. YK has received honoraria and institutional research funding from Daiichi Sankyo. AI, MD, YK, SY, SS, AH, KS, OM, NI, KN, YH, MY, SK, TA, YM, and YK declare that they have no conflict of interest.

References

- 1 Khorana AA. Venous thromboembolism and prognosis in cancer. *Thromb Res*. 2010; 125 (6): 490-493.
- 2 Aonuma AO, Nakamura M, Sakamaki K et al. Incidence of cancer-associated thromboembolism in Japanese gastric and colorectal cancer patients receiving chemotherapy: A single-institutional retrospective cohort analysis (Sapporo CAT study). *BMJ Open*. 2019; 9 (8): e028563.
- 3 Timp JF, Braekkan SK, Versteeg HH et al. Epidemiology of cancer-associated venous thrombosis. *Blood*. 2013; 122 (10): 1712-1723.
- 4 Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. *Thromb Haemost*. 2017; 117 (2): 219-230.

- 5 Key NS, Khorana AA, Kuderer NM et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. *J Clin Oncol*. 2020; 38 (5): 496-520.
- 6 Mandalà M, Falanga A, Roila F et al. Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. *Ann Oncol*. 2011; 22 Suppl 6: vi85-92.
- 7 Farge D, Frere C, Connors JM et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. *Lancet Oncol*. 2019; 20 (10): e566-e581.
- 8 Lyman GH, Carrier M, Ay C et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer. *Blood Adv*. 2021; 5 (4): 927-974.
- 9 Peris M, Jiménez D, Maestre A et al. Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism. *Eur Respir J*. 2016; 48 (5): 1360-1368.
- 10 Kraaijpoel N, Di Nisio M, Mulder FI et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: Results from the Hokusai VTE cancer study. *Thromb Haemost*. 2018; 118 (8): 1439-1449.
- 11 Mulder FI, van Es N, Kraaijpoel N et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE cancer study. *Thromb Res*. 2020; 185: 13-19.
- 12 Khorana AA, Noble S, Lee AYY et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: Guidance from the SSC of the ISTH. *J Thromb Haemost*. 2018; 16 (9): 1891-1894.
- 13 National Comprehensive Cancer Network. NCCN guideline on cancer-associated venousthromboembolic disease. Version 1. 2020. https://www.nccn.org/professionals/physician_g...; 2020.
- 14 Nakamura M, Yamada N, Asamura T et al. Safety and effectiveness of Edoxaban in Japanese patients with venous thromboembolism - An interim analysis of data from a Japanese postmarketing observational study (ETNA-VTE-Japan). *Circ J*. 2019; 83 (6): 1394-1404.
- 15 Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *J Thromb Haemost*. 2005; 3 (4): 692-694.
- 16 Raskob GE, van Es N, Verhamme P et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. *N Engl J Med*. 2018; 378 (7): 615-624.

- 17 Raskob GE, van Es N, Segers A et al. Edoxaban for venous thromboembolism in patients with cancer: Results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. *Lancet Haematol*. 2016; 3 (8): e379-387.
- 18 Young AM, Marshall A, Thirlwall J et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). *J Clin Oncol*. 2018; 36 (20): 2017-2023.
- 19 Gary T, Belaj K, Steidl K et al. Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact on short-term survival. *Br J Cancer*. 2012; 107 (8): 1244-1248.
- 20 Li A, Manohar PM, Garcia DA et al. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. *Thromb Res*. 2019; 180: 37-42.
- 21 Ageno W, Vedovati MC, Cohen A et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: Results from the Caravaggio study. *Thromb Haemost*. 2020.
- 22 Li G, Lip GYH, Holbrook A et al. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: A systematic review and meta-analysis of observational studies. *Eur J Epidemiol*. 2019; 34 (2): 173-190.
- 23 Trujillo-Santos J, Di Micco P, Dentali F et al. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. *Thromb Haemost*. 2017; 117 (2): 382-389.
- 24 Carrier M, Abou-Nassar K, Mallick R et al. Apixaban to prevent venous thromboembolism in patients with cancer. *N Engl J Med*. 2019; 380 (8): 711-719.
- 25 Khorana AA, Soff GA, Kakkar AK et al. Rivaroxaban for Thromboprophylaxis in high-risk ambulatory patients with cancer. *N Engl J Med*. 2019; 380 (8): 720-728.
- 26 O'Connell C, Escalante CP, Goldhaber SZ et al. Treatment of cancer-associated venous thromboembolism with low-molecular-weight heparin or direct oral anticoagulants: Patient selection, controversies, and caveats. *Oncologist*. 2021; 26 (1): e8-e16.
- 27 Desai J, Kolb JM, Weitz JI et al. Gastrointestinal bleeding with the new oral anticoagulants—defining the issues and the management strategies. *Thromb Haemost*. 2013; 110 (2): 205-212.
- 28 Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. *World J Gastroenterol*. 2017; 23 (11): 1954-1963.

- 29 Chan EW, Lau WC, Leung WK et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: A population-based study. *Gastroenterology*. 2015; 149 (3): 586-595.e583.
- 30 Ray WA, Chung CP, Murray KT et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. *JAMA*. 2018; 320 (21): 2221-2230.

Tables

Table 1. Baseline patient characteristics

Characteristics (n = 53)	Result
Male sex, n (%)	28 (53)
Age	
Median, years (range)	65.3 (38–83)
≥75 years, n (%)	9 (17.0)
ECOG PS, n (%)	
0	38 (71.7)
1	14 (26.4)
2	1 (1.9)
Body weight	
Mean ± SD, kg	59.7 ± 8.9
≤60 kg, n (%)	28 (52.8)
Platelet count of 50,000–100,000/μL, n (%)	2 (3.8)
Pretreatment creatinine clearance, n (%)	
≤50 mL/min	2 (3.8)
>50–80 mL/min	29 (54.7)
>80 mL/min	22 (41.5)
VTE diagnosis, n (%)	
PE with or without DVT	11 (20.8)
Proximal DVT	40 (75.5)
Distal DVT	4 (7.5)
Location of DVT, n (%)	
Internal jugular vein	7 (13.2)
Subclavian vein	12 (22.6)
Axillary vein	1 (1.9)
Superior vena cava	13 (24.5)
Portal vein	1 (1.9)
Superior mesenteric vein	1 (1.9)
Ovarian vein	4 (7.5)

Femoral vein	1 (1.9)
Soleal vein	3 (5.7)
Anterior tibial vein	1 (1.9)
Posterior tibial vein	1 (1.9)
Peroneal vein	2 (3.8)
<hr/>	
Currently receiving cancer treatment, n (%)	
Chemotherapy for advanced/metastatic cancer	48 (90.6)
Neo-adjuvant chemotherapy	2 (3.8)
Adjuvant chemotherapy	3 (5.7)
<hr/>	
Primary tumor type, n (%)	
Colorectal	30 (56.6)
Esophageal	6 (11.3)
Gastric	6 (11.3)
Pancreatic	9 (17.0)
Other	2 (3.8)
<hr/>	
CVC placement, n (%)	
No	6 (11.3)
Yes	47 (88.7)

Abbreviations: CVC, central venous catheter; DVT, deep-vein thrombosis; ECOG PS, Eastern Cooperative Oncology Group performance status; PE, pulmonary embolism; VTE, venous thromboembolism

Table 2. Primary outcome

Outcome (n = 53)	No. of patients (%)
MB or CRNMB	6 (11.3)
MB	4 (7.5)
Criteria defining MB*	
Clinically overt and decrease in the hemoglobin level of ≥ 2 g/dL over 24 h	2 (3.8)
Clinically overt and transfusion of ≥ 2 units of packed red cells	2 (3.8)
Clinically overt and located at a critical site (e.g., intracranial, retroperitoneal)	2 (3.8)
Clinically overt and contributing to death	0 (0)
Sites of MB, no./total no. (%)	
GI	3/4 (75)
Upper GI	1/4 (25)
Lower GI	1/4 (25)
Site unknown	1/4 (25)
Intracranial	1/4 (25)
Clinical presentation severity category**, no./total no. (%)	
Category 1	1/4 (25)
Category 2	1/4 (25)
Category 3	2/4 (50)
Category 4	0
CRNMB	2 (3.8)
Criteria defining CRNMB	
Overt bleeding requiring medical intervention	0
Unscheduled contact with a physician	0
Interruption of edoxaban	2 (3.8)
Discomfort or impairment of activities of daily living	0
Site of CRNMB, no./total no. (%)	
Gastrointestinal (stoma)	1 (50)
Genitourinary (vagina)	1 (50)

Abbreviations: CRNMB, clinically relevant non-major bleeding; GI, gastrointestinal; MB, major bleeding

*One patient had three reasons: decreased hemoglobin levels, transfusion of red cells, and critical site bleeding.

**Classification of the clinical presentation of major bleeding events: Category 1, bleeding events presenting without any clinical emergency; Category 2, all bleeding events requiring certain measures without necessitating urgent measures that could not be classified to any of the other three categories; Category 3, bleeding events causing a major medical emergency; such as hemodynamic instability, or cerebral bleeding presenting with neurologic symptoms; and Category 4, bleeding events that were fatal before or almost immediately after entering the hospital.

Table 3. Changes of the thrombus volume during 3 months of edoxaban administration

Thrombus*	No. of patients (%)
Investigators' assessment (n = 53)	
Exacerbation	3 (5.7)
No change	5 (9.4)
Improved	9 (17.0)
Disappeared	35 (66.0)
No data	1 (1.9)
Time to blood clot disappearance (days, n = 35), mean $\pm$ SD (range)	62.1 $\pm$ 18.2 (25–98)
Central review (n = 60)†	
	No. of blood clots (%)
Exacerbation	4 (6.7)
No change	7 (11.7)
Improved	17 (28.3)
Disappeared	28 (46.7)
No data	4 (6.7)
Time to blood clot disappearance (days, n = 28), mean $\pm$ SD (range)	59.8 (16–97, 19.5)

*Both the investigator's assessment and central review adjudicated the evaluation of changes in the thrombus volume into the following categories:

Exacerbation, new thrombus formation or apparent increase in the thrombus volume versus baseline. An increase in the thrombus diameter of 4 mm or more was defined as an increase.

No change, neither exacerbation nor improvement.

Improved, loss of blood clots, or apparent reduction of the thrombus volume versus baseline. Shrinkage was indicated by a reduction of the thrombus volume of at least 50%.

Disappeared, the absence of a thrombus present at baseline.

†Central review was performed for each blood clot (n = 60), not for each patient (n = 53).

Table 4. Adverse events during the entire observation period

Events	n = 53	
	Any grade*	Grade 3 or higher
	n (%)	n (%)
Bleeding events (overall)	15 (28.3)	3 (5.7)
Thalamic bleeding	1 (1.9)	1 (1.9)
Epistaxis	7 (13.2)	0
Gingival bleeding	1 (1.9)	0
Tracheal bleeding	1 (1.9)	0
Upper gastrointestinal bleeding	1 (1.9)	1 (1.9)
Lower gastrointestinal bleeding	2 (3.8)	0
Gastrointestinal bleeding (site unknown)	1 (1.9)	1 (1.9)
Genital bleeding	1 (1.9)	0
Anal bleeding	2 (3.8)	0
Hematuria	2 (3.8)	0
Laboratory test abnormalities (overall)	18 (34.0)	8 (15.1)
Anemia	7 (13.2)	2 (3.8)
Leukopenia	6 (11.3)	1 (1.9)
Neutropenia	10 (18.9)	7 (13.2)
Platelet count decreased	1 (1.9)	0
INR increased	4 (7.5)	0
AST elevation	1 (1.9)	0
ALT elevation	1 (1.9)	0
Hypoalbuminemia	1 (1.9)	0
Hypomagnesemia	1 (1.9)	0
Creatinine elevation	1 (1.9)	0
Proteinuria	2 (3.8)	0
Non-hematologic AE (overall)	23 (43.4)	3 (5.7)
Anorexia	5 (9.4)	1 (1.9)

Alopecia	1 (1.9)	0
Constipation	2 (3.8)	0
Cough	1 (1.9)	0
Diarrhea	5 (9.4)	1 (1.9)
Dysgeusia	6 (11.3)	0
Edema limbs	2 (3.8)	0
Fatigue	3 (5.7)	0
Hand-Foot skin reaction	2 (3.8)	0
Headache	1 (1.9)	0
Hiccups	1 (1.9)	0
Hoarseness	2 (3.8)	0
Hyperpigmentation	1 (1.9)	0
Hypertension	2 (3.8)	2 (3.8)
Malaise	4 (7.5)	0
Nausea	3 (5.7)	0
Peripheral neuropathy	4 (7.5)	0
Pruritus	1 (1.9)	0
Stomatitis	2 (3.8)	0
Vomiting	1 (1.9)	0

*Grading was evaluated according to Common Terminology Criteria for Adverse Events v4.03

Abbreviations: AE, adverse event; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, prothrombin time–international normalized ratio

Figures

Figure 1

CONSORT flow chart of patient enrollment.

Adults presenting with new asymptomatic venous thromboembolism (VTE), deep vein thrombosis (DVT), or pulmonary thromboembolism (PE) during systemic chemotherapy after a histological diagnosis of gastrointestinal cancer were eligible to participate in the study. In this study, the primary endpoint (safety) was evaluated in a population of patients who received the therapeutic research drug at least once.

Figure 2

Edoxaban medication status. Starting daily dose of edoxaban according the presence of the following dosage adjustment factors: body weight ≤ 60 kg, creatinine clearance ≤ 50 mL/min, and concomitant use of P-glycoprotein inhibitors (e.g., quinidine).

Figure 3

The primary and secondary outcomes. Kaplan–Meier curves of the primary and secondary outcomes within 3 months. (A) MB or CRNMB, (B) MB alone, (C) thrombus recurrence and death, and (D) thrombus recurrence alone. The inset presents the same data on an enlarged y-axis.

CRNMB, clinically relevant non-major bleeding; MB, major bleeding

Figure 4

Subgroup analysis according to edoxaban DAFs. Kaplan–Meier curves of the cumulative incidence of (A) MB or CRNMB and (B) CAT recurrence or death according to the presence of DAFs. CAT, cancer-associated thrombosis; CRNMB, clinically relevant non-major bleeding; DAF, dose adjustment factor; MB, major bleeding

Figure 5

Subgroup analysis according to the edoxaban dose (15 mg vs. 30 mg. vs. 60 mg).

Kaplan–Meier curves of the cumulative incidence of (A) MB or CRNMB and (B) CAT recurrence or death according to the presence of DAFs.

CAT, cancer-associated thrombosis; CRNMB, clinically relevant non-major bleeding; DAF, dose adjustment factor; MB, major bleeding

Figure 6

Subgroup analysis according to the primary cancer site.

Kaplan–Meier curves of the cumulative incidence of (A) MB or CRNMB and (B) CAT recurrence or death according to the presence of DAFs.

CAT, cancer-associated thrombosis; CRNMB, clinically relevant non-major bleeding; DAF, dose adjustment factor; MB, major bleeding

Figure 7

Subgroup analysis according to renal function (creatinine clearance: ≤ 50 mL/min vs. > 50 –80 mL/min vs. > 80 mL/min). Kaplan–Meier curves of the cumulative incidence of (A) MB or CRNMB and (B) CAT recurrence or death according to the presence of DAFs. CAT, cancer-associated thrombosis; CRNMB, clinically relevant non-major bleeding; DAF, dose adjustment factor; MB, major bleeding

Figure 8

Subgroup analysis according by body weight (≤ 60 kg vs. > 60 kg). Kaplan–Meier curves of the cumulative incidence of (A) MB or CRNMB and (B) CAT recurrence or death according to the presence of DAFs. CAT, cancer-associated thrombosis; CRNMB, clinically relevant non-major bleeding; DAF, dose adjustment factor; MB, major bleeding

Figure 9

Subgroup analysis according by age (<75 years vs. ≥ 75 years). Kaplan–Meier curves of the cumulative incidence of (A) MB or CRNMB and (B) CAT recurrence or death according to the presence of DAFs. CAT, cancer-associated thrombosis; CRNMB, clinically relevant non-major bleeding; DAF, dose adjustment factor; MB, major bleeding

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementalAppendix.docx](#)
- [SupplementalFigureS1.bmp](#)
- [SupplementalFigureS2.bmp](#)
- [SupplementalFigureS3.bmp](#)
- [SupplementalFigureS4.bmp](#)
- [SupplementalFigureS5.bmp](#)
- [SupplementalFigureS6.bmp](#)